Saga of the newer generation pills and the concept of risk

Reproductive Health Matters

Volumn 4, Issue 7, 1996, Pages 158-161

  Henry, Alice ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 10644232355     PISSN: 09688080     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-8080(96)90020-8     Document Type: Article

References (18)

1. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception (CSCDSHC), 1995. Venous thromboembolic disease and combined oral contraceptives: results of an international multicentre case-control study. Lancet. 346:1575-82. The calculated risk (odds ratio from 3 to 6) was at the low end compared to previous reports, which range from a relative risk for oral contraceptive users compared to non-users of from 2:1 to 11:1.
2. Venous thromboembolism includes both deep vein thrombosis and pulmonary embolism.
3. WHO CSCDSHC, 1995. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet. 346:1582-88.
4. Mills AM, Wilkinson CL, Bromham DR et al, 1996. Guidelines for prescribing combined oral contraceptives (Letter). BMJ. 312:121-22.
5. Spitzer WO, Lewis MA, Heinemann LAJ et al, 1996. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. BMJ. 312:83-87.
6. Jick H, Jick SS, Gurewich V et al, 1995. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using contraceptives with differing progestogen components. Lancet. 346:1589-93.
7. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM et al, 1995. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestogen. Lancet. 346:1593-1596.
8. Carnell D, Karcher H, Lie LG et al, 1995. Third generation oral contraceptives - the controversy. BMJ. 311:1589-90.
9. Wynn V, Crook D, Godsland IF et al, 1995. Committee's action will undermine further research and development (Letter). BMJ. 311:1639-40.
10. Lewis MA, Spitzer WO, Heinemann LAJ et al, 1996. Third generation oral contraceptives and risk of myocardial infarction: an international case-control study. BMJ. 312:88-90.
11. Guillebaud J, 1995. If a woman has not had a thrombotic event in years of use she is unlikely to have one now (Letter). BMJ. 311:637-38.
12. Smith C, 1996. How one clinic's practice conforms with CSM's advice (Letter). BMJ. 312:576.
13. Ketting E, 1996. CSM's advice will harm women's health worldwide (Letter). - Stewart-Brown S and Pyper C, 1996. CSM should rethink its approach for such announce-ments. BMJ. 312:576.
14. Ketting E, 1996. CSM's advice will harm women's health worldwide (Letter). - Stewart-Brown S and Pyper C, 1996. CSM should rethink its approach for such announce-ments. BMJ. 312:576.
15. McPherson K, 1996. Third generation oral contraception and venous thromboembolism (Editorial). BMJ. 312:68-69.
16. Vandenbroucke JP, Bloemenkamp KWM, Helmerhorst FM et al, 1996. Safety of combined oral contraceptives (Letter). Lancet. 347:547-48.
17. Armstrong JL, Reid M and Bigrigg A, 1995. Effect on behaviour of women attending a family planning clinic (Letter). BMJ. 311:1637. See also other letters on these issues in the pages following this.
18. Mihill C and Quinn S, 1996. Abortions up by 10pc following pill scare. Guardian. 15 April.